2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult, Animal Model
PAPER

3172 Clinical significance of natural killer cells in severity stratification and therapeutic response in aplastic anemia

Nanxi Dong, MD, Jiayi Chen, MD2, Yu Zhang Jr, MD3, Zhengwei Tan, MD4, Jingjing Liu, MD5, Qijia Zheng6, Baodong Ye, MD, PhD7, Hangchao Li8
1 The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
4 The First Medical College of Zhejiang Chinese Medical University, Hangzhou, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
6 The First Medical College of Zhejiang Chinese Medical University, Hangzhou, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
8 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China

Introduction

Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome, classified as severe (SAA) or non-severe (NSAA) based on disease severity. T cell-mediated hematopoietic stem cell (HSC) injury is a cornerstone of AA pathogenesis. However, the role of natural killer (NK) cells in disease severity and prognosis remains controversial. This study aimed to characterize peripheral blood NK cell counts and subsets in SAA and NSAA patients and correlate them with clinical outcomes.

Method

This Retrospective study enrolled 62 AA patients (16 SAA, 46 NSAA) and 17 healthy donors (HD) at Zhejiang Provincial Hospital of Chinese Medicine (2024–2026). Bone marrow NK subsets (total NK, CD56bright, CD56dim) were measured by flow cytometry at diagnosis. Treatment responses (CR/PR/NR) were assessed at 6 months per international criteria. Group comparisons used one-way ANOVA with Welch's correction and Games-Howell post-hoc tests. NSAA patients were stratified by ROC-derived NK cutoff, and progression rates were compared. Single-cell RNA sequencing (scRNA-seq) was performed on a subset (9 SAA, 10 NSAA, 4 HD) using the BD Rhapsody platform.

Result

The 79 subjects included 16 SAA, 46 NSAA, and 17 HD. The mean ages of the three groups were 41.31±21.95, 43.87±16.57, and 39.12±11.90 years, respectively, with no statistically significant difference across groups (P = 0.627). Female proportions were 31.3%, 43.5%, and 29.4%, respectively (P = 0.570), confirming that baseline demographic characteristics were well balanced among the three cohorts.

 

Flow cytometric profiling revealed a stepwise expansion of bone marrow NK cells from HD through NSAA to SAA. Total NK frequencies increased progressively across groups (HD: 9.84±5.72%; NSAA: 13.60±7.33%; SAA: 16.95±10.34%; P = 0.037), with SAA exhibiting a significant elevation relative to HD (P = 0.028). A similar pattern emerged for CD56bright cells (HD: 0.71±0.29%; NSAA: 1.02±0.84%; SAA: 1.74±1.54%; P = 0.009), wherein SAA surpassed both NSAA (P = 0.029) and HD (P = 0.010). CD56dim cells followed the same graded trend (HD: 9.04±5.71%; NSAA: 11.28±7.49%; SAA: 16.39±6.27%; P = 0.008), with SAA again significantly higher than NSAA (P = 0.03) and HD (P = 0.009). Although NSAA consistently showed higher NK frequencies than HD across all subsets, these differences did not reach statistical significance.

 

When stratified by 6-month therapeutic outcome, patients fell into three response categories: CR (n=11), PR (n=39), and NR (n=12). Total NK frequencies differed markedly across these groups (CR: 9.75±5.47%; PR: 14.30±6.46%; NR: 20.76±11.22%; P<0.001), as did CD56bright (CR: 0.73±0.57%; PR: 0.86±0.68%; NR: 1.93±1.83%; P = 0.004) and CD56dim subsets (CR: 8.07±4.77%; PR: 13.93±8.15%; NR: 19.28±10.38%; P = 0.038). Post-hoc testing indicated that NR patients harbored significantly higher total NK and CD56bright counts relative to both CR (P<0.01 for both) and PR (P = 0.019 and P = 0.008, respectively). CD56dim cells were similarly elevated in NR versus CR (P = 0.003), though the NR–PR comparison did not achieve significance (P = 0.117). No significant intergroup differences were observed between CR and PR across any NK parameter, suggesting that elevated NK levels portend inferior treatment responsiveness.

 

Within the NSAA cohort (n=47), ROC analysis identified 9.98% as the optimal total NK threshold for predicting progression (AUC=0.727, P = 0.023). Among patients with high NK counts (n=27), 5 (18.52%) progressed to SAA, compared with 2 of 20 (10%) in the low-NK subgroup—a difference that did not reach statistical significance (P = 0.480).

 

ScRNA-seq confirmed a graded increase in NK cells from HD to NSAA to SAA. CellChat analysis demonstrated that NK–HSC interaction strength followed the identical hierarchy, with the strongest crosstalk in SAA, supporting a pathogenic role for NK cells in HSC injury.

Conclusion

We provide the first systematic evidence that marrow NK cell counts are associated with more severe AA, inferior treatment response, and NSAA progression. ScRNA-seq confirmed escalating NK–HSC interaction with disease worsening. Marrow NK levels thus represent a candidate biomarker for risk stratification and individualized therapy in AA.

Nanxi Dong, MD: No relevant conflicts of interest to declare.